Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets

Author：      

Publisher： Spandidos Publications

E-ISSN： 1791-244X|36|1|173-185

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.36, Iss.1, 2015-01, pp. : 173-185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impaired secretion of active GLP‐1 in patients with hypertriglyceridaemia: A novel lipotoxicity paradigm?

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Histological Markers for Endothelial Cells in Endogenous and Transplanted Rodent Pancreatic Islets

By  

Pancreatology, Vol. 2, Iss. 2, 2002-04 ,pp. : 155-162

Karger

Access to resources Recommend Favorite

Endothelial Cells in Endogenous and Transplanted Pancreatic Islets: Differences in the Expression of Angiogenic Peptides and Receptors

By  

Pancreatology, Vol. 6, Iss. 1-2, 2006-04 ,pp. : 86-95

Karger

Access to resources Recommend Favorite

GSK2374697, a long duration glucagon‐like peptide‐1 (GLP‐1) receptor agonist, reduces postprandial circulating endogenous total GLP‐1 and peptide YY in healthy subjects

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 1007-1010

John Wiley & Sons Inc

Access to resources Recommend Favorite

GSK2374697, a long duration glucagon‐like peptide‐1 (GLP‐1) receptor agonist, reduces postprandial circulating endogenous total GLP‐1 and peptide YY in healthy subjects

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 1007-1010

John Wiley & Sons Inc

Access to resources Recommend Favorite